Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harbin Pharmaceutical Group CoSHSE:600664 +0.56%66 Return-on-Tangible-Asset is 4.62% as of Mar. 2026, which is 57% above its 10-year median of 2.95. GuruFocus rates SHSE:600664 with a GF Score™ of 66/100 and a GF Value™ of ¥3.51 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks worse than 54.02% on this metric.
The historical rank and industry rank for Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:600664'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -9.21 Med: 2.95 Max: 5.64
Current: 2.26
During the past 13 years, Harbin Pharmaceutical Group Co's highest Return-on-Tangible-Asset was 5.64%. The lowest was -9.21%. And the median was 2.95%.
SHSE:600664's Return-on-Tangible-Asset is ranked worse than 54.02% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.04
vs SHSE:600664: 2.26
Harbin Pharmaceutical Group Co (SHSE:600664) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Related Terms
Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co Return-on-Tangible-Asset Chart
SHSE:600664 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.62% mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Return-on-Tangible-Asset of 4.62% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Harbin Pharmaceutical Group Co and its competitors. This is 57% above median its historical median of 2.95. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #544 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset too high?
Harbin Pharmaceutical Group Co's current Return-on-Tangible-Asset of 4.62% is 57% above median its 10-year median of 2.95. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.04. Harbin Pharmaceutical Group Co's value of 4.62% is 52% above this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #544 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #544 out of 1007 companies for Return-on-Tangible-Asset. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.04. Harbin Pharmaceutical Group Co's value of 4.62% is 52% above this benchmark. While the company's 10-year median is 2.95 vs. the industry median of 3.04, Harbin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.04, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current Return-on-Tangible-Asset of 4.62% is 52% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current Return-on-Tangible-Asset is 4.62%, which is 57% above median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥8.91 — trading 153.8% above its estimated fair value. The current Return-on-Tangible-Asset is 4.62%, which is 57% above median its 10-year median of 2.95 and 52% above the Drug Manufacturers industry median of 3.04. Harbin Pharmaceutical Group Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Return-on-Tangible-Asset is 4.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥8.91 is trading 153.8% above its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600664:
Return-on-Tangible-Asset: 4.62% (57% above median its 10-year median of 2.95)
GF Value™: ¥3.51 vs. price of ¥8.91 (153.8% above fair value)
Industry Position: 52% above the Drug Manufacturers median (#544 of 1007)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
66GF Score
Get the complete analysis for SHSE:600664
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
